Cargando…
Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies
Although acute myeloid leukemia (AML) is primarily a disease of older adults (age ≥60 years), the optimal treatment for older adults remains largely undefined. Intensive chemotherapy is rarely beneficial for frail older adults or those with poor-risk disease, but criteria that define fitness and/or...
Autores principales: | Pettit, Kristen, Odenike, Olatoyosi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677344/ https://www.ncbi.nlm.nih.gov/pubmed/26697412 http://dx.doi.org/10.3389/fonc.2015.00280 |
Ejemplares similares
-
Venetoclax for the treatment of newly diagnosed acute myeloid
leukemia in patients who are ineligible for intensive
chemotherapy
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2019) -
Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Xia, Leiming, et al.
Publicado: (2023) -
Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy
por: Brackman, Deanna, et al.
Publicado: (2022) -
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Yamamoto, Kazuhito, et al.
Publicado: (2021) -
Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment
por: Ikezoe, Takayuki, et al.
Publicado: (2022)